← Stock Trading Canary · All insider profiles
INSIDER PROFILE · NL
van den Ouden DM
Managing Director / Chief Executive Officer
Profile key: nl|van den ouden dm
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 0
- Purchases · 24M
- 5
- Average purchase
- €7,500
- Gross purchase value
- €37,500
- Last purchase
- 2025-09-26
- Completed 20D events
- 5.0
- Outcome status
- PASS
Latest company: TME Pharma N.V.
Companies: TME Pharma N.V.
Post-purchase outcomes
Benchmark-relative outcomes are available against AEX.
- Excess return = stock return − AEX return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 100.0% (5/5) | 100.0% (5/5) | +7.3% | +6.7% | +1.9% |
| 20D | 5Developing | 100.0% (5/5) | 0.0% (0/5) | -7.1% | -7.4% | -9.6% |
| 60D | 5Developing | 100.0% (5/5) | 0.0% (0/5) | -42.3% | -41.6% | -43.3% |
| 120D | 5Developing | 100.0% (5/5) | 0.0% (0/5) | -30.2% | -29.7% | -31.7% |
Research patterns
- First purchase in 12M
- 1/5
- Large purchase ≥ €100k
- 0/5
- Cluster buying · 15D
- 5/5
- Buying the dip · ≥20% below prior 52W high
- 5/5
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.